Table 1. Changes between baseline and longer-term follow-up for secondary outcome measures.

	Baseline		Change from baseline		*P-value
	Omega-3 (n=41)	Placebo (n=40)	Omega-3 (n=41)	Placebo (n=40)
PANSS score
Total	59.9 (2.8)	57.2 (2.8)	−13.9 (3.3)	0.2 (3.3)	0.003
Positive	15.0 (0.7)	14.2 (0.7)	−5.1 (0.9)	−0.8 (0.9)	0.002
Negative	14.0 (0.9)	13.6 (0.9)	−3.1 (1.1)	0.4 (1.1)	0.024
General	30.9 (1.4)	29.4 (1.4)	−5.6 (1.8)	0.6 (1.8)	0.015
MADRS score	17.6 (1.5)	18.8 (1.6)	−7.3 (2.0)	−2.7 (2.0)	0.117
GAF score	61.0 (2.5)	60.0 (2.5)	7.7 (2.7)	−0.8 (2.7)	0.028

GAF, Global Assessment of Functioning; MADRS, Montgomery–Asberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale.

NB: values that refer to mean (s.e.).

^*P-values that refer to contrasts from the repeated-measures mixed model.